Brandling-Bennett A D, Jackson R S, Halstead S B, Campbell C C, Herrmann K L, Modlin J F, Meyers J D, Witte J J
Am J Dis Child. 1976 Oct;130(10):1081-4. doi: 10.1001/archpedi.1976.02120110043005.
Three years after receiving rubella vaccine, 1,060 elementary school children living on the island of Maui, Hawaii, were revaccinated with either HPV-77 DE-5 or RA 27/3 rubella vaccine given subcutaneously or intranasally in order to compare the effectiveness of these two vaccines in raising antibody titers. RA 27/3 was the more effective booster vaccine, producing fourfold or greater titer rises in 20.1% of recipients, including 80% of children with hemagglutination-inhibiting antibody titers less than or equal to 1:40 at the time of revaccination, intranasal revaccination was not significantly more effective than subcutaneous revaccination, although it did elicit higher titers in children who responded. Responses differed according to the vaccine that children had received three years earlier. Because antibody titers have persisted in vaccinated children, routine administration of a second dose of rubella vaccine is not currently recommended.
在接种风疹疫苗三年后,夏威夷毛伊岛的1060名小学生再次接种了HPV - 77 DE - 5或RA 27/3风疹疫苗,通过皮下或鼻内注射,以比较这两种疫苗提高抗体滴度的效果。RA 27/3是更有效的加强疫苗,在20.1%的接种者中产生了四倍或更高的滴度升高,包括在再次接种时血凝抑制抗体滴度小于或等于1:40的儿童中的80%,鼻内再次接种并不比皮下再次接种显著更有效,尽管它确实在有反应的儿童中引发了更高的滴度。反应因儿童三年前接种的疫苗而异。由于接种疫苗的儿童中抗体滴度持续存在,目前不建议常规接种第二剂风疹疫苗。